Australia’s RMIT University has signed a commercial licence agreement with start-up Atmo Biosciences for ingestible sensors developed to measure gases in the gut in order to diagnose gut-related disorders.
Under the terms of the agreement, Atmo will gain exclusive rights to commercialise the gut sensors. RMIT will in turn get royalties from the sale of products by Atmo.
The deal also enables the firm to conduct Phase II clinical trials for the new technology, which is expected to be available in the market within four years.
Atmo will also work towards improving the existing technology and expand the range of gases detected by the sensors.
The researchers will focus on various gut biomarkers such as those related to small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and ulcerative colitis.
Atmo Biosciences CEO Mal Hebblewhite said: “One in five people worldwide suffer from a gastrointestinal disorder in their lifetime, and almost a third of these cases remain unresolved, often due to difficulty in diagnosis.
“The Atmo Gas Capsule has the potential to close this gap by offering the ability to identify previously undiagnosed conditions. This will provide relief to the millions of patients who suffer daily without targeted therapy to relieve their symptoms.”
Designed in the form of an electronic capsule, the gut sensors can identify and measure gaseous biomarkers in real-time, enabling diagnosis of gut disorders and targeted therapy.
After ingestion, the sensors transmit data through a handheld device and mobile app to the cloud.
RMIT, in partnership with Monash University, conducted in-human clinical trials in January this year to investigate the use of these sensors in tracking gut health.
Findings showed that the sensors can clinically monitor digestion and normal gut health, and effectively measure microbiome activities in the stomach.